Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020
January 08 2020 - 4:05PM
Business Wire
– Corporate presentation by CEO Casey Lynch
will be webcast live – Lynch will also participate in a roundtable
session earlier in the day
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage
biopharmaceutical company pioneering a novel disease-modifying
therapeutic approach to treat what it believes to be a key
underlying cause of Alzheimer’s and other degenerative
diseases, today announced Casey Lynch, the company’s chief
executive officer, chair, and co-founder will present at the 3rd
Annual Neuroscience Innovation Forum on Sunday, January 12, 2020 at
3:45 p.m. PST / 6:45 p.m. EST. The Forum will take place on the eve
of the J.P. Morgan Healthcare Conference in downtown San
Francisco.
A live webcast of the corporate presentation will be accessible
at the Investor Calendar page under the News & Events heading
of the Cortexyme investor site (ir.cortexyme.com). The webcast will
be archived at that location for 90 days.
In addition to the corporate presentation, Ms. Lynch will
participate in a plenary session at the Forum, “Advances in
Alzheimer’s & Other Cognitive Disorders,” earlier in the day.
This event will feature brief presentations from a panel of
neuroscience drug development experts followed by a roundtable
discussion moderated by co-chairs Christian Jung, Partner at the
Dementia Discovery Fund, and Sumant Kulkarni, Managing Director of
Biotechnology Equity Research at Canaccord Genuity LLC.
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical
company pioneering a novel, disease-modifying therapeutic approach
to treat what it believes to be a key underlying cause of
Alzheimer’s disease and other degenerative diseases. Cortexyme is
targeting a specific, infectious pathogen found in the brain of
Alzheimer’s patients and tied to neurodegeneration and
neuroinflammation in animal models. The company’s lead
investigational medicine, COR388, is the subject of the GAIN Trial,
an ongoing Phase 2/3 clinical study in patients with mild to
moderate Alzheimer’s. To learn more about Cortexyme, visit
www.cortexyme.com or follow @Cortexyme on Twitter.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. Factors that could cause
actual results to differ include, but are not limited to, the risks
and uncertainties described in the section titled “Risk Factors” in
the final prospectus related to Cortexyme’s initial public offering
filed with the Securities and Exchange Commission on May 9, 2019
and Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 12, 2019. Forward-looking
statements contained in this press release are made as of this
date, and Cortexyme undertakes no duty to update such information
except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200108005835/en/
Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415)
994-0040
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024